Table 2.
Study timetable
| Visit 1 | Visit 2 | Visit 3 - 9 | Visit 10 | Visit 11 -12 | Visit 13 | Visit 14 | Visit 15 | |
|---|---|---|---|---|---|---|---|---|
| |
up to one month and a reference period1 of 2 h before Visit 2 |
0 h2 |
1–7 h (every hour) ± 5 min |
8 h ± 5 min |
9 and 10 h ± 5 min |
16 h ± 30 min |
24 h ± 30 min |
72 h ± 1 h |
| Informed consent |
● |
|
|
|
|
|
|
|
| Eligibility criteria |
● |
● |
|
|
|
|
|
|
| Medical history |
● |
|
|
|
|
|
|
|
| Concomitant medication |
● |
● |
● |
● |
● |
● |
● |
● |
| Physical examination |
● |
|
|
|
|
|
● |
|
| Vital signs3 |
● |
● |
● |
● |
● |
● |
● |
● |
| Pregnancy test4 |
● |
|
|
|
|
|
|
|
| Placement of the CGM |
|
● |
|
|
|
|
|
|
| CGM calibration |
|
● |
|
|
|
|
|
|
| Continuous glucose and lactate monitoring |
|
● |
● |
● |
● |
● |
● |
up to every 2 h |
| Recalibration |
|
|
|
● |
|
|
|
|
| Central venous blood sampling for the BGA5 |
|
|
● |
● |
● |
● |
● |
|
| Central venous blood sampling for central laboratory measurement6 |
|
● |
|
● |
|
● |
● |
|
| Removal of CGM |
|
|
|
|
|
|
|
● |
| Assessment of unwanted events/effects | ● | ● | ● | ● | ● | ● | ● |
1 Priming, tempering and transient oscillation of the sensor systems.
2 Within 2 h of transfer to the recovery room or intensive care unit.
3 Heart rate, blood pressure, and tympanic body temperature.
4 Only females with reproductive potential.
5 Samples used to assess blood glucose, blood lactate, haematocrit, and haemoglobin.
6 Samples used to assess blood glucose and blood lactate levels.
CGM: continuous glucose monitor; BGA: blood gas analyser.